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Objectives
• Background
• Regulatory Update
• Summarize the basic principles and strategies of an antimicrobial
stewardship program
• Biomarkers and Rapid Diagnostics
• Describe appropriate antibiotic therapy strategies

Question
Which of the following is true?
1. Clinicians perceive antimicrobial overuse is a problem
generally, but not locally
2. Other medical specialties responsible for overuse
3. Antimicrobial resistance is a macro problem but of
limited concern at the bedside
4. All of the above

Answer is all of the above

Complex problem
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Antibiotics as miracles
(“No downside risk, so
why not try?”)

Antibiotics: Good when
used well, better when
used thoughtfully
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Background
Consequences of inappropriate antibiotic use

Crisis in Infectious Diseases
Widespread

antimicrobial drug resistance
Increasing number of patients who are
immunosuppressed
Emergence of new pathogens
Reemergence of older pathogens
Decrease new drug development
Dysbiosis due to antimicrobial therapy

Clin Infect Dis 2017; 64:823-828

Collateral Damage of Antibiotic Use
• Average child receives 10-20
courses of antibiotics before
age 18
• Antibiotics affect our resident
microbiota and may not fully
recover after a course of
antibiotics
• Overuse of antibiotics may be
contributing to obesity, DM,
IBD, allergies, and asthma

Nature 2011;476:393

Antimicrobial Resistance
• Increases mortality and morbidity
• Antibiotic-resistant infections have been estimated to
cost the US healthcare system over $20 billion
annually and over 35 billion in societal costs

Emerg Infect Dis 2001; 7:286
Arch Intern Med 2003; 163:972
Infect Control Hosp Epidemiol 2003; 24:642
Nat Rev Microb 2004; 2:251
Clin Infect Dis 2009; 49:1175-84

Practices That Promote Resistance
• Misuse of antibiotic(s)
• Overuse of antibiotics in outpatient settings.
• Overuse of antibiotics in hospital settings.
• Poor compliance with regimens.
• Use of antibiotics in animals. (80% of antibiotics sold to farms)

One Health Antibiotic Stewardship
Collaborative
• Multi-partner initiative to address antibiotic use
• Inter-agency approach by government
• MDH, MN Board of Animal Health, MN Ag,
Pollution Control Agency
• Stakeholders from academia, human and veterinary
clinical practice, professional and industry
associations, healthcare systems, producer
organizations

Courtesy Dr Ruth Lynfield

Antibiotic Use Drives Resistance
Date of antibiotic introduction
Penicillin
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1940
Penicillin-R
Staphylococcus

Methicillin
1960
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Methicillin-R
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Vancomycin
1972

Levofloxacin
1996

1988
Vancomycin-R
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Levofloxacin-R
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Date of resistance identified
http://www.cdc.gov/drugresistance/about.html

Ceftaroline
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Ceftaroline-R
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Taylor et al Can J Infect Dis Med Microbiol. 2015 Mar-Apr; 26(2): 85–89.
Antimicrobial prescribing practice in Australian hospitals. December 2016.
Magill et al JAMA 2014;312(14):1438-1446

Classes with highest increase in use US hospitals

Source: CDC. Antibiotic Use in the United States, 2017: Progress and Opportunities.
https://www.cdc.gov/getsmart/pdf/stewardship-report.pdf

Misuse of antibiotics
Underuse

• An antibiotic is not used when it could
improve health

Unnecessary
use

• An antibiotic is not indicated e.g. non
bacterial infections

Inappropriate
use

• Incorrect timing, choice, dose, route, or
duration

Inappropriate use of antibiotics

Suboptimal or inadequate use
• administration is delayed in a critically ill patient,
• choice of an antimicrobial with an unnecessarily broad spectrum
or too narrow a spectrum
• dose is too high or too low
• duration is too long or too short
• treatment is not streamlined or changed when microbiological
culture data become available
• use in patient with an allergy to the agent
• drug – drug interactions
• poor patient adherence to the prescribed treatment

Inappropriate use in hospitals

Common problems
Antimicrobial not indicated
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Infect Control Hosp Epidemiol 2015; 36:142-152
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Setting National Targets:
Outpatient Antibiotic Prescribing

(CARB National Action Plan)

47 million unnecessary antibiotic
prescriptions per year
Fleming-Dutra et al. JAMA 2016;315(17): 1864-1873.
http://www.pewtrusts.org/~/media/assets/2016/05/antibioticuseinoutpatientsettings.pdf; CARB Action Plan

Outcomes of antibiotic misuse

• Development of resistant organisms, Clostridium
difficile infections
• Patient harm such as treatment failure adverse drug
events and increased mortality
• Increase healthcare and societal costs.

It’s a Matter of Patient Safety
 Adverse events from antibiotics range from minor to severe

• Side effects like rash or antibiotic-associated diarrhea
• Allergic reactions, including anaphylaxis (life-threatening)

 1 in 1000 antibiotic prescriptions leads to an emergency department (ER) visit for an adverse event
• 142,000 ER visits per year for antibiotic-associated adverse events
• Antibiotics are most common cause of drug-related emergency department visits for children

 Long-term consequences: growing evidence that antibiotics associated with chronic disease through
disruption of the microbiota and microbiome

Shehab, et al. Clin Infect Dis. 2008 Sep 15;47(6):735-43. Bourgeois, et al. Pediatrics. 2009;124(4):e744-50.
Linder. Clin Infect Dis. 2008 Sep 15;47(6):744-6. Vangay, et al. Cell host & microbe 2015; 17(5): 553-564.

GLOBAL DIMENSIONS
Estimate: By 2050, 10 Million Deaths Attributed to AMR Every Year
Costing World Economy $100 Trillion

Review on Antimicrobial Resistance (AMR), 2014. Antimicrobial Resistance: Tackling
a crisis for the health and wealth of nations. London, UK http://amr-review.org

Regulatory

Stewardship Seats at the Table

SIDP

Payors/

Consumers

Infection Prevention and Epidemiology

CARB

https://www.cdc.gov/drugresistance/pdf/national_action_plan_for_combating_antiboticresistant_bacteria.pdf

Core Elements for Antibiotic Stewardship Programs

http://www.cdc.gov/getsmart/healthcare/implementation/core-elements.html

CDC Core Elements
1. Leadership commitment: Dedicate necessary human, financial,
and IT resources
2. Accountability: Appoint a single leader responsible for program
outcomes-this is usually a physician
3. Drug expertise: Appoint a single pharmacist leader to support
improved prescribing
4. Act: Take at least one prescribing improvement action, such as
“antibiotic timeout”
5. Track: Monitor prescribing and antibiotic resistance patterns
6. Report: Regularly report to interdisciplinary team the prescribing
and resistance patterns, and steps to improve
7. Educate: Offer team education about antibiotic resistance and
improving prescribing practice

Centers for Disease Control and Prevention. MMWR. March 2014. 63; 194-200.

CDC’s Core Elements Adopted by
• The Joint Commission for their
antibiotic stewardship
standard
• DNV for their antibiotic
stewardship standard
• CMS-funded Hospital
Improvement Innovation
Networks (HIINs)
• AHRQ Comprehensive Unitbased Safety Program
(CUSP)

Joint Commission & Antimicrobial
Stewardship

https://www.jointcommission.org/topics/hai_antimicrobial_stewardship.aspx

State Antibiotic Stewardship Legislative Policies
• California
• Senate Bills 1311 (2014) and 361 (2015) require antibiotic stewardship
programs in all California hospitals and nursing homes

• Missouri
• Senate Bill 579 (2016) requires that all non-psychiatric hospitals
establish stewardship programs and report antibiotic use to CDC’s
National Healthcare Safety Network (NHSN) Antimicrobial Use Option

Antimicrobial Stewardship
program (ASP)
Basic principles and implementation strategies

The Challenge
• How to initiate and improve
antibiotic stewardship efforts
• Proving that it works
• Clinical outcomes
• Decrease resistance
• Changing the antibiotic
prescribing culture
• Hardwiring the process
• Continuing to show financial
benefit to maintain funding
and support of efforts

The Problem with Antimicrobial
Stewardship
• Everyone thinks they know what it is
But who knows what it should be?
– Which strategies are most effective?
– How to assess their effectiveness?

Antimicrobial Stewardship: Definition
• A system of informatics, data collection, personnel, and
policy/procedures which promotes the optimal selection,
dosing, and duration of therapy for antimicrobial agents
throughout the course of their use.
• An effective antimicrobial stewardship program will limit
inappropriate and excessive antimicrobial use, but more
importantly improve and optimize therapy and clinical
outcomes for the individual infected patient.

Ohl CA. Seminar Infect Control 2001;1:210-21.
Ohl CA. J. Hosp Med. In press.
Dellit TH, et. al. Clin Infect Dis. 2007;44:159-177

Antimicrobial Stewardship: Goals
• Improve patient outcomes
• Optimize selection, dose and duration of Rx
• Reduce adverse drug events including secondary infection (e.g. C.
difficile infection)
• Reduce morbidity and mortality
• Prevent or slow the emergence of antimicrobial resistance
• Reduce length of stay
• Reduce health care expenditures
MacDougall CM and Polk RE. Clin Micro Rev 2005;18(4):638-56.
Ohl CA. J. Hosp Med. In press.
Dellit TH, et. al. Clin Infect Dis. 2007;44:159-177

Strategies
Appropriate antibiotic therapy

The 5 Ds
. Right Diagnosis
– What infection syndrome is being treated?
--Does the patient have an infection?
– Have appropriate diagnostic tests been collected?

1

2. Right Drug
– Demonstrated effective per local epidemiology
– Safest
– Least “resistance-ogenic” – narrowest spectrum
– Least expensive
3. Right Dose
4. Right Duration:
– Minimal duration undefined for many indications
– For most: resolution of systemic and improvement in local manifestations

5. Right De-escalation: change to narrowest spectrum/safest/least expensive regimen when:
– Justified by culture results (positive or negative)
– Clinical improvement (e.g., IV to PO switch)

Four Moments of Antibiotic Decision Making
1. Does my patient have an infection
that requires antibiotics?

2. Have I ordered appropriate cultures
before starting antibiotics? What
empiric therapy should I initiate?
3. A day or more has passed. Can I
stop antibiotics? Can I narrow
therapy or change from IV to oral
therapy?
4. What duration of antibiotic therapy
is needed for my patient's
diagnosis?
AHRQ Safety Program for Improving Antibiotic Use. 2018.

Obtain Cultures Prior to Starting Antibiotics!
• Develop a process to ensure cultures are properly and
consistently ordered
• Nursing to ensure safe/timely collection of specimens from
appropriate source
• Develop processes to ensure cultures are properly and
promptly transported and processed

ARHAI. Antimicrobial stewardship: “start smart-then focus”. Guidance for
antimicrobial stewardship in hospitals (England). November, 2011.
Eur J Clin Microbiol Infect Dis. 2009;28(2009):1447-1456.
CDC. Core Elements of Hospital Antibiotic Stewardship Programs. 2014.
Am J Infect Control. 2013;41(2013):365-367.

Clinical Pearl: Appropriate Specimen
Collection and Cultures
Culture results guide better patient care decisions
• Wounds

• Recommend against superficial swab, likely colonizing organisms
• Preferred samples are pus and tissue
• Surgical wounds – recommend contacting MD prior to culture collection, consider
wound care consult if available for cleansing/debridement prior to sample

• Blood cultures

• Separate peripheral venipunctures using aseptic technique are preferred
• Drawing blood for cultures from indwelling catheters should be avoided unless
the catheter is thought to be the source of bacteremia
• Label specimen and collection site and time

• Urine

• Evaluation of the patient’s symptoms is critical before ordering urine culture
• Screening for asymptomatic bacteriuria (ABU) is not recommended except in
pregnancy and before an invasive urological procedure
• A urinalysis should be performed before a urine culture is ordered. Urine with
>10 WBC/HPF with symptoms should have a urine culture if patient has
symptoms.

Clinical Pearl: Appropriate Specimen Collection and Cultures (2)
• Stool for C. difficile
• clinically significant diarrhea is defined as 3 or more unformed stools samples
within 24 hours
• Only watery or unformed loose stool should be submitted (Bristol 6 or 7)
• If patient has been on laxatives in the last 48 hours cancel order and allow at
least 48 hours without laxatives to reassess
• Testing to evaluate for cure is not recommended.
• PCR does not distinguish colonization versus infection, therefore indications
for testing are very important.

Choice of Empiric Agent
MAXIMIZE
COVERAGE

MINIMIZE
SELECTION

against most likely
pathogens

for resistance

Considerations in Empiric Choice
Host
Type of infection
Community-Acquired vs LTC
vs Hospital-Acquired
Underlying comorbidities

Microbe
Local antibiogram
ICU vs Non-ICU

Drug
Prior antibiotic therapy
Selection based on potential for resistance
Need for multiple agents

Front-end Approach
Physician writes order
for “Restricted Drug”

Order arrives in pharmacy,
pharmacist informs the
physician and primary nurse
that the drug is
“restricted”/”Not part of the
pathway”/”non-formulary”

Prescribing Physician and the
“GATE KEEPER” converse

Approval or Alternative
Antibiotic Selected

Front-end Approach
• Advantages
• Direct control over
antimicrobial use
• Effective control of
antimicrobial use
during outbreaks
• Decreased
inappropriate use of
antimicrobials (and
thus costs)

• Disadvantages

• Personnel needs
• Antagonistic
relationship (loss of
autonomy)
• Therapy may be delayed
• Manipulation of the
system
• ID physicians often
exempt
• Effectiveness in
decreasing resistance is
less clear
• No impact on deescalation or duration

Prospective Audit and Feedback (back-end approach)
Physician writes
order

Antibiotic is
Dispensed

1.) Antibiotic
Change/Continued
based on Practice
Guidelines

At a later date, antibiotics are
reviewed by interdisciplinary
team

2.) Prescribing
physician contacted and
recommendation made

(Targeted list of antibiotics,
C/S mismatches, ICU patients,
duration)

Prospective Audit and Feedback
• Advantages
• Prescriber autonomy
maintained
• Educational
opportunity provided
• Patient information
can be reviewed
before interaction
• Inappropriate
antimicrobial use
decreased
• Impact duration and
de-escalation

• Disadvantages
• Compliance voluntary
• Identification of
patients may require
computer support
• Prescribers may be
reluctant to change
therapy if the patient is
doing well
• Some inappropriate
antimicrobial use
permitted (with
retrospective audit)

Guidelines/ClinicalPathways /EBOS*
• Protocols to guide therapy for a given infection
• Specific to institutional formulary, patient populations, and
resistance patterns
• Evidence-based

• Advantages

• Disadvantages

– Appropriate
antimicrobial use
may increase
– Form of education

*Guidelines may not be appropriate for all situations. Decisions should be based on
clinical judgment and consideration for individual patients.

– Adherence is usually
voluntary
– “Cookbook medicine”
– Maintenance is
required

De-Escalation: Goals
• Changing from a broad-spectrum antibiotic to one with a narrower spectrum if
appropriate
• Eliminate overlapping or combination therapy targeting causative organism or
• Stopping antimicrobial therapy when a non-infectious etiology most likely
• Administer antimicrobial therapy for the correct duration
• Decrease antimicrobial exposure → reduce adverse events
• Cost savings

De-escalation Timeline
Infected Patient
Site (s) of Infection
Community vs. Hospital

Baseline
BroadSpectrum
Empirical
Therapy

Laboratory tests
Collection of infected materials
Gram Stain

1 hours

24-48 hours

Culture Results

Identification of organism

Discontinue Agents
48-72 hours

Sensitivity
Abx
De-escalation

72-96 hours

Precision and time

Antimicrobial Spectrum of Activity

De-escalation of Therapy
• Decrease number of agents and/or spectrum of activity as appropriate in
response to culture results and clinical outcomes
• Optimizing initial therapy may oppose steps to limit use of broad-spectrum
agents
• De-escalation recognizes both aspects
• Advantages
– Allows initial use of broadspectrum therapy
– Narrows therapy when
appropriate
– Improves outcomes
– Reduces adverse events
– May influence future
prescribing behavior
– Decreases inappropriate use
of antimicrobials
– Reduces costs

• Disadvantages
– Prescribers may be reluctant
to change therapy if the
patient is doing well
– If not done correctly, may
narrow therapy
“inappropriately”

De-escalation: Lessons learned
The most common reasons for not de-escalating:
• Lack of conclusive microbiology
• Continued use of broad-spectrum antimicrobial therapy

• Diagnostic uncertainty
• Treatment of fever, colonization and/or contamination

• Insecurity
• Treatment of noninfectious syndrome associated with fever

• Duration longer than necessary leading to increase adverse
events
• Highlight duration of therapy for broad-spectrum antibiotics
• Engage all members of the interdisciplinary healthcare team in monitoring

Antibiotic Time Out
• Trigger tool to stop and
reassess antibiotic therapy
• Targeted at all providers for
Med/Surg patients
• Guided assessment at 72 hrs
• Treatment duration
recommendations included
for key infections

Duration: Avoid automatic 10-14 Day Courses
• New Evidence for Duration of Therapy
– Uncomplicated urinary tract infection: 3-5 days1
– Community-acquired pneumonia: 3-7 days2
– Ventilator-associated pneumonia: 8 days3
– CR-BSI Coagulase-negative staphylococci: 5-7 days4
– Acute Hem Osteomyelitis in children-21 days5
– Meningococcal meningitis-7 days6
– Uncomplicated secondary peritonitis with source control: 4-7 days7
– Uncomplicated SSTI 5 days8
1.
2.
3.
4.
5.
6.
7.
8.

Clin Infect Dis 1999; 29:745-758
Clin Infect Dis 2007; 44:S27-72
JAMA 2003; 290:2588-2598
Clin Infect Dis 2009; 49:1-45
Pediatr Infect Dis 2010; 29:1123-1128
N Engl J Med 1997; 336:708-716
Clin Infect Dis 2010: 50:133-164
Arch Intern Med 2004; 164:1669-1674

Case
This is a 46 year old female admitted with hypotension,
fever, and flank pain. She has no underlying medical or
urologic problems. Her urine showed pyuria and
bacteriuria, the peripheral WBC was 16,000/mm3. She
was admitted to the ICU and empirically started on
_______.
What would you start?

1.
2.
3.
4.

Piperacillin/tazobactam
Cefepime
Ceftriaxone
Levofloxacin

And Now the Rest of the Story
She was admitted to the ICU and started on cefepime. A PICC line was inserted. By
day 2, she stabilized and was transferred to the floor. Her urine and blood grew E.
coli sensitive to all tested antibiotics except ampicillin. The results were not
available until after she was transferred to the floor. She was continued on
cefepime. On day 7, she spiked a new fever. Blood cultures were drawn and
grew__________. Antibiotics were changed to _________. On day 12 her WBC
increased to 30,000/mm3 and she reported unformed stools. Your
diagnosis_____________
Where there opportunities to improve?
1. de-escalation
2. duration

Effective Implementation
Getting started

In press Am J Infect Control

ASP Phase 1 Foundational
• MD/ PharmD Champion
• Multidisciplinary team
• Gap Assessment
• Assess staff resources
• Competency/Training Planning
• Communication Plan for facility
• CEO support for AMP by
approval of gap and action plan

• Selecting Physician
Champion
• Complete gap assessment
and action plan as a team
• Determine staffing needs to
adequately resource AMP
activities
• Create competency/training
plan for all disciplines based
on current knowledge and
involvement
• Invite CEO to AMP team
meeting to discuss plan,
resources, and support

The establishment of a well supported, multidisciplinary ASP
infrastructure ensures an ASP is sustainably integrated into
facility practices rather than dependent on a single person

Antimicrobial Stewardship Team
Multidisciplinary Team Approach to Optimizing Clinical Outcomes*
Hospital
Epidemiologist

Hospital and Nurse
Administration

Infection

Infectious
Diseases
Director,
Quality

Prevention

AMP Directors
• Cl. Pharmacist

Medical
Information
Systems

• Physician Champion

Nursing

Clinical
Pharmacy
Specialists

Microbiology
Laboratory
Decentralized
Pharmacy
Specialist
Modified Clin lnfect Dis 2007;44:159-177.

Chairman,
P&T
Committee
Partners in
Optimizing
Antimicrobial Use such as
ED, hospitalists, intensivists
and surgeons

*based on local resources

Physician To Do List
• Select local physician champion
• Develop an effective antimicrobial stewardship team
• Education the medical staff and administration about
the urgency and value of an effective antimicrobial
stewardship team
• Assure that microbiology is aware of how to detect
new resistance mechanisms (e.g. CREs, NDM1) and
new CLSI break points

Infectious Diseases Physicians: Leading the Way in
Antimicrobial Stewardship

Pharmacy Leadership
• Pharmacy leadership is consistently identified as a must for
stewardship in hospitals.
• Pharmacists often play a lead role in implementing improvement
interventions and monitoring antibiotic use. Should have some
training in infectious diseases. (e.g. MAD-ID, SIDP, SHEA)
• Many programs are co-lead by a physician and pharmacist.

Role of Infection Prevention
• Timely communication to team when MDROs are
identified
• Prevention of MDRO in health care facilities
• Monitor trends in antimicrobial resistance
• Educate team about NHSN definitions of HAIs
• Collaborate with microbiology, pharmacy, medical
staff, and administration to plan and implement
effective interventions

AJIC 2012; 40:94

Microbiology Stewardship:
Obtain Cultures Prior to Starting Antibiotics!
• Develop a process to ensure cultures are properly and
consistently ordered-cultures should have an indication
• Develop a process to ensure cultures are properly and
consistently obtained
• Develop processes to ensure cultures are properly and
promptly transported and processed
• Develop standards for and assess reliability of processes
for ordering and obtaining a culture
• Link molecular diagnostics to stewardship

Are nurses underutilized in ASP?
RN

PharmD

ID-MD

Patient triage and isolation

X

Accurate allergy history

X

Timely antibiotic initiation

X

Daily progress monitor and report

X

X

X

Preliminary antibiotic dosing

X

X

X

Adverse event monitoring

X

X

Change in patient condition

X

IV to PO adjustment

X

X

X

Patient education

X

X

X

X
X

X

Olans RN et al. Clin Infect Dis. 2016; 62:84-89

Defining a Role for Nursing Education in Staff Nurse Participation in Antimicrobial
Stewardship. Olans RD et al. J Contin Educ Nurs. 2015; 46:318-21.
“Identified a need for more education and also an interest in the area for practicing
nurses.”

Evidence-based guidelines for implementation and measurement of
antibiotic stewardship interventions in inpatient populations including
long-term care were prepared by a multidisciplinary expert panel of the
Infectious Diseases Society of America and the Society for Healthcare
Epidemiology of America. The panel included clinicians and investigators
representing internal medicine, emergency medicine, microbiology,
critical care, surgery, epidemiology, pharmacy, and adult and pediatric
infectious diseases specialties. These recommendations address the best
approaches for antibiotic stewardship programs to influence the optimal
use of antibiotics

Clin Infect Dis 2016;62(10):e51–e77

Infection Prevention and Epidemiology

Suggested Measures

Modified Curr Infect Dis Rep 2014; 16:433

Suggested Measures continued

Modified Curr Infect Dis Rep 2014; 16:433

ASP Phase 2
• Associated with clinical and
economic benefit
• Antimicrobial formulary review
• Review metrics (e.g. DOT, CDI, expenditures)
• Review CAP and SCIP core measure
• Microbiology
• CLSI susceptibility reporting
• Review new CLSI breakpoints
• Appropriate use of microbiology document
with emphasis on obtaining appropriate
cultures before starting antimicrobial
therapy for new septic episodes
• Dose optimization
• Weight-based dosing
• Renal dosing
• IV to PO

• Review facility by-laws and state
scope of practice for automatic
interchanges
• P&T and Med Exec approval
• Many institutions have these
activities implemented (CAP/SCIP)
• Routine IV to PO/ Renal Dosing

ASP Phase 3
• Kinetic dosing
• Vanc and AG
• Prolonged infusion for pipercillin/tazobactam and
carbapenems

• Approve institutional guidelines
• CAP, HAP, UTI and ABU, MRSA, VAP, intra-abdominal,
surviving sepsis, C. difficile
• Timely and appropriate use of antibiotics based on
approved institutional guidelines and local antibiograms
• Optimize duration based on evidence-based peer review
publications
• Evaluate use agents based on local needs (front/back-end
approach)
• Suggested drugs: daptomycin, linezolid,
echinocandins, tigecycline, and carbapenems
• Clinical pharmacy rounding with team

• Involve nursing staff early in
extended infusion work
• Meropenem and P/T
prolonged infusion
recommendation can be
combined with formulary
change to P&T
• Evaluate ability of pharmacist
to cover drug regimen
reviews and rounding
consistently

ASP Phase 4
• De-escalation “72 hour time-out”
• Suggestions: review charts with positive
blood cultures, 3 or more antibiotics for
≥72 hours, drug-bug mismatches, or
antibiotics without a positive culture,
duration
• Review and/or implement rapid diagnostics,
point of care testing, and biomarkers (PCT)for
appropriate use
• Ongoing antibiogram development (e.g. unit
specific)
• Report approved metrics to all stakeholders
on a regular basis
•Clinical decision support/CPOE

• Overlap will occur with
various phases.
• Expectation is for facility
to complete elements of
each phase in a timely
manner.
• Advanced programs can
start on other phases
before the suggested
timelines.
• Synergize ASP with Core
Measures and Sepsis
Programs
• Provide guidance on use
of PCT and rapid
diagnostics

Rapid diagnostics

Old

New

TAT

TTI

Turn Around
Time

Time To
Intervention
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Rapid Diagnostic Tests
• Biomarkers of infection/inflammation
•
•
•
•
•

WBC
ESR
CRP
Lactate
PCT

• Gram stain

Procalcitonin Dynamics

PCT Guidance

Lancet 2010;375:463-74

Rapid Diagnostic Tests (2)
• Culture dependent
•
•
•
•
•

Rapid biochemical identification
Proteomic identification (MALDI-TOF)
BCID microarrays, nanoparticle, and PNA-FISH
Rapid phenotypic AST
Detection of selected resistance genes

Rapid Diagnostic Tests (3)
• Culture independent
• Direct antigen detection tests
• Single target or limited multiplex NAATs
• In lab and now POCTs

• Syndromic multiplex panels for BSI, GI, RT, and CNS
infections
• Direct detection of BSI by PCR/T2 MRI and PCR/ESI/MS

CASE
This is a 54 year-old female readmitted to the hospital for probably
deep sternal SSI. Three weeks earlier she underwent a CAB, MV
repair, and an AVR. She received “appropriate” surgical prophylaxis.
She is a known diabetic.

CASE Continued (2)
• On readmission she was febrile (102o), BP 90/60, P-120;
• Lungs--decreased breath sounds on left, no rubs, -purulence from lower sternum.
• White count was 18,000 with 15% bands, lactate 3.1, creat
2.1, blood cultures were drawn

Case continued(3)

•ID was called in ED
•Gram stain was performed which showed—
rapid diagnostic test performed within 2
hours of arrival to ED
What antibiotic(s) would you start?

1.
2.
3.
4.

Cefazolin
Vancomycin
Nafcillin
Daptomycin

Case continued(4)
• Vancomycin and piperacillin/tazobactam by ED physician
was started. ID physician discontinued
piperacillin/tazobactam.
• At 12 hours blood cultures were positive for grampositive cocci in clusters
• Culture from sternum was identified at S aureus the
next morning sensitivities pending
• Patient was taken to surgery for sternal debridement
• TEE indicated a vegetation on her AV

Scenario #1 Traditional Method -Suspected Infection
• Fluid or Tissue Sample
• Gram’s Stain
• Bacteria present? If so, Gram - or +
• Results in minutes

• Sample incubated in culture media
• Usually 24 hours for growth

• Biochemical testing to determine organism
• Minutes to 24 hours

• Susceptibility testing
• Another 24-48 hours
• At 48 hours, susceptibilities revealed MSSA

Scenario #2 Rapid Molecular Methods
•

Technologies available
• Polymerase chain reaction (PCR)
• Multiplex PCR
• Nanoparticle Probe Technology
• Matrix-Assisted Laser Desorption/Ionization Time-ofFlight Mass Spectrometry (MALDI-TOF MS)
• From blood culture MALDI confirmed S aureus and PCR
indicated this was a MSSA within 4 hours of + blood
culture.
• Total time 16 hours vs 48 hours by traditional methods
What would you do now?
Does it matter since vancomycin covers both MSSA and
MRSA?

ß-lactam vs Vancomycin for
MSSA Bacteremia
Percent Mortality

30-Day In Hospital Mortality
25
20

15
10
5
0
ß-lactam

Vancomycin +
Vancomycin*
*Statistically significant
ß-lactam
Antibiotic Regimen

BMC Inf Dis. 2011; 11: 279-85.
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How Will We Get There?

Technical
Work
Evidencebased
interventions

Adaptive
Work
Local culture

Why does Culture Matter?
• Safety culture influences the effectiveness of other safety
and quality interventions
• Can enhance or inhibit effects of other interventions
• Safety culture can change through intervention
• Best evidence so far for culture interventions that use
multiple components (e.g.: CUSP, Positive Deviance)

Haynes et al., 2011; Morello et al., 2012; Van Nord et al.,
2010; Weaver et al. Ann Intern Med. 2013;158:369-374.

Physician Barriers
•
•
•
•
•
•

Physician accountability and acceptance of need for improvement
Misperceptions
Misalignment of incentives
Lack of definition of appropriate use of antimicrobial agents
Lack of standardized, risk-adjusted measures
Adaptive/behavioral changes needed to change prescribing practices

Surviving Sepsis Campaign Mandate

Treat first and then evaluate later
Intensive Care Med 2018; 44:925-928

Inconvenient Truths
• High rate of overdiagnosis
• Approach promotes excess antimicrobial use and increases unintended consequences
•
•
•
•
•

C difficile infections
Acute kidney injury and other side effects (e.g. hepatitis, rash, cytopenias)
Missed culture opportunities (antibiotics administered before appropriate cultures obtained)
Selection for MDROs
Alteration of microbiome-dysbiosis

• Less than 60% of patients admitted to ICU with diagnosis of “sepsis” are confirmed (Crit
Care Med 2015; 19:319)

• Time to antibiotics matters for septic shock, but evidence is less convincing for patients
with possible sepsis without shock
• Two recent studies confirmed association between delay in antimicrobial administration and
mortality in patients with septic shock but little or no association for patients without shock (N Engl J
Med 2017; 376:2235-2244; Am J Respir Crit Care Med 2017; 196:856-863)

• Randomized trial of antibiotics administered in the ambulance versus administered in ED for
patients with suspected sepsis found mortality was the same in both groups. More than 90%
of patients enrolled in study had infection alone or sepsis without shock. (Lancet Respir Med 2018;
6:40-50)

Key Elements for Successful ASP
• Establish compelling need and goals for ASP
• Senior leadership support
• Effective local physician champion

• Adequate resources and competencies (pharmacy, infection preventionist [IP],
microbiology, information technology [IT])
• Primary objectives: optimize clinical outcomes and reduce adverse events, not
reduce costs
• Good teamwork
• Agreed upon process and outcome measures
• ASP should be across the continuum of care

Stewardship is a Team Sport
• Indicators of High Performing Teams
• A high degree of interaction and communication among
all members with mutual respect
• The team directs energy towards the team vision and
goals and less energy towards individual’s own agenda
• A sense of common ownership

• Commitment and trust
• Members feel great personal satisfaction from
belonging to the team
• Team members share loyalty and group identification

SUCCESS IS NOT FINAL,
FAILURE IS NOT FATAL:

IT IS THE COURAGE TO
CONTINUE THAT COUNTS

Winston Churchill

